MIAMI – Medications in development for the treatment of attention-deficit/hyperactivity disorder (ADHD) target specific behaviors, such as impulsive aggression, and genes that involve the glutamatergic network, new research shows. In the first of two studies presented here at the American Society of Clinical Pharmacology (ASCP), researchers reported on improvements in the management of impulsive aggression in children with ADHD with long-term therapy, lasting more than 6 months, of extended-release molindone (SPN-810, Supernus) as an adjunct to stimulant monotherapy.